361 related articles for article (PubMed ID: 26205655)
1. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
2. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis.
May M; Burger M; Otto W; Hakenberg OW; Wieland WF; May D; Hofstädter F; Götz S; Niessl N; Fritsche HM; Birnkammer K; Gilfrich C; Peter J; Jain A; Koch S; Lebentrau S; Riedmiller H; Rössler W; Denzinger S; Brookman-May S; Gunia S
BJU Int; 2013 Aug; 112(4):E383-90. PubMed ID: 23305250
[TBL] [Abstract][Full Text] [Related]
3. The potential utility of geminin as a predictive biomarker in breast cancer.
Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
[TBL] [Abstract][Full Text] [Related]
4. DNA replication licensing factor MCM2, geminin, and Ki67 define proliferative state and are linked with survival in oral squamous cell carcinoma.
Al-Hazmi N; Alhazzazi T; Williams G; Stoeber K; Al-Dabbagh R
Eur J Oral Sci; 2018 Jun; 126(3):186-196. PubMed ID: 29745471
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
[TBL] [Abstract][Full Text] [Related]
6. DNA replication licensing and cell cycle kinetics of normal and neoplastic breast.
Shetty A; Loddo M; Fanshawe T; Prevost AT; Sainsbury R; Williams GH; Stoeber K
Br J Cancer; 2005 Nov; 93(11):1295-300. PubMed ID: 16278669
[TBL] [Abstract][Full Text] [Related]
7. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma.
Dudderidge TJ; Stoeber K; Loddo M; Atkinson G; Fanshawe T; Griffiths DF; Williams GH
Clin Cancer Res; 2005 Apr; 11(7):2510-7. PubMed ID: 15814627
[TBL] [Abstract][Full Text] [Related]
8. Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.
Nishimukai A; Inoue N; Kira A; Takeda M; Morimoto K; Araki K; Kitajima K; Watanabe T; Hirota S; Katagiri T; Nakamori S; Akazawa K; Miyoshi Y
PLoS One; 2017; 12(9):e0184508. PubMed ID: 28886153
[TBL] [Abstract][Full Text] [Related]
9. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
[TBL] [Abstract][Full Text] [Related]
10. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.
Tökés AM; Szász AM; Geszti F; Lukács LV; Kenessey I; Turányi E; Meggyesházi N; Molnár IA; Fillinger J; Soltész I; Bálint K; Hanzély Z; Arató G; Szendröi M; Kulka J
J Clin Pathol; 2015 Apr; 68(4):274-82. PubMed ID: 25595275
[TBL] [Abstract][Full Text] [Related]
11. Cell kinetic markers in cutaneous squamous and basal cell carcinoma of the head and neck.
Alaeddini M; Etemad-Moghadam S
Braz J Otorhinolaryngol; 2022; 88(4):529-532. PubMed ID: 32972865
[TBL] [Abstract][Full Text] [Related]
12. Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance.
Shomori K; Nishihara K; Tamura T; Tatebe S; Horie Y; Nosaka K; Haruki T; Hamamoto Y; Shiomi T; Nakabayashi M; Ito H
Gastric Cancer; 2010 Aug; 13(3):177-85. PubMed ID: 20820987
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
[TBL] [Abstract][Full Text] [Related]
14. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas.
Torres-Rendon A; Roy S; Craig GT; Speight PM
Br J Cancer; 2009 Apr; 100(7):1128-34. PubMed ID: 19293805
[TBL] [Abstract][Full Text] [Related]
15. Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer.
Dudderidge TJ; McCracken SR; Loddo M; Fanshawe TR; Kelly JD; Neal DE; Leung HY; Williams GH; Stoeber K
Br J Cancer; 2007 May; 96(9):1384-93. PubMed ID: 17406359
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder.
Krüger S; Thorns C; Stöcker W; Müller-Kunert E; Böhle A; Feller AC
Eur Urol; 2003 Feb; 43(2):138-45. PubMed ID: 12565771
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.
Yang J; Ramnath N; Moysich KB; Asch HL; Swede H; Alrawi SJ; Huberman J; Geradts J; Brooks JS; Tan D
BMC Cancer; 2006 Aug; 6():203. PubMed ID: 16882345
[TBL] [Abstract][Full Text] [Related]
18. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
19. MCM2 expression levels predict diagnosis and prognosis in gastric cardiac cancer.
Liu M; Li JS; Tian DP; Huang B; Rosqvist S; Su M
Histol Histopathol; 2013 Apr; 28(4):481-92. PubMed ID: 23329420
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic significance of DNA replication licensing factors in head and neck diffuse large B-cell lymphoma.
Etemad-Moghadam S; Ghaseminejad-Bandpey A; Mahmoodzadeh H; Alaeddini M
Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Apr; 133(4):462-469. PubMed ID: 35153182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
